371 related articles for article (PubMed ID: 25681711)
21. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase.
Muratore G; Goracci L; Mercorelli B; Foeglein Á; Digard P; Cruciani G; Palù G; Loregian A
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6247-52. PubMed ID: 22474359
[TBL] [Abstract][Full Text] [Related]
22. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.
Hu Y; Zhang J; Musharrafieh R; Hau R; Ma C; Wang J
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885544
[TBL] [Abstract][Full Text] [Related]
23. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
[TBL] [Abstract][Full Text] [Related]
24. Anti-influenza A virus activity of uridine derivatives of 2-deoxy sugars.
Krol E; Wandzik I; Gromadzka B; Nidzworski D; Rychlowska M; Matlacz M; Tyborowska J; Szewczyk B
Antiviral Res; 2013 Oct; 100(1):90-7. PubMed ID: 23911991
[TBL] [Abstract][Full Text] [Related]
25. Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546.
Basu A; Komazin-Meredith G; McCarthy C; Antanasijevic A; Cardinale SC; Mishra RK; Barnard DL; Caffrey M; Rong L; Bowlin TL
ACS Infect Dis; 2017 May; 3(5):330-335. PubMed ID: 28301927
[TBL] [Abstract][Full Text] [Related]
26. New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
Khomenko TM; Zarubaev VV; Kireeva MV; Volobueva AS; Slita AV; Borisevich SS; Korchagina DV; Komarova NI; Volcho KP; Salakhutdinov NF
Bioorg Med Chem Lett; 2020 Dec; 30(24):127653. PubMed ID: 33129992
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates.
Li H; Li M; Xu R; Wang S; Zhang Y; Zhang L; Zhou D; Xiao S
Eur J Med Chem; 2019 Feb; 163():560-568. PubMed ID: 30554131
[TBL] [Abstract][Full Text] [Related]
28. Germacrone inhibits early stages of influenza virus infection.
Liao Q; Qian Z; Liu R; An L; Chen X
Antiviral Res; 2013 Dec; 100(3):578-88. PubMed ID: 24095670
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanism of the enhanced viral fitness contributed by secondary mutations in the hemagglutinin protein of oseltamivir resistant H1N1 influenza viruses: modeling studies of antibody and receptor binding.
Behera AK; Basu S; Cherian SS
Gene; 2015 Feb; 557(1):19-27. PubMed ID: 25479009
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and inhibitory effects of novel pyrimido-pyrrolo-quinoxalinedione analogues targeting nucleoproteins of influenza A virus H1N1.
Lin MI; Su BH; Lee CH; Wang ST; Wu WC; Dangate P; Wang SY; Huang WI; Cheng TJ; Lin OA; Cheng YS; Tseng YJ; Sun CM
Eur J Med Chem; 2015 Sep; 102():477-86. PubMed ID: 26310893
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Antiviral Activities of Neoechinulin B and Its Derivatives.
Nishiuchi K; Ohashi H; Nishioka K; Yamasaki M; Furuta M; Mashiko T; Tomoshige S; Ohgane K; Kamisuki S; Watashi K; Kuramochi K
J Nat Prod; 2022 Jan; 85(1):284-291. PubMed ID: 34967639
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and structure-activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion.
Zhu Z; Li R; Xiao G; Chen Z; Yang J; Zhu Q; Liu S
Eur J Med Chem; 2012 Nov; 57():211-6. PubMed ID: 23059548
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
35. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
[TBL] [Abstract][Full Text] [Related]
36. Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus.
Li H; Chen L; Li S; Liao Y; Wang L; Liu Z; Liu S; Song G
Bioorg Med Chem Lett; 2019 Sep; 29(18):2675-2680. PubMed ID: 31371135
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Inhibition of Influenza A Virus Adhesion by Di- and Trivalent Hemagglutinin Inhibitors.
Lu W; Du W; Somovilla VJ; Yu G; Haksar D; de Vries E; Boons GJ; de Vries RP; de Haan CAM; Pieters RJ
J Med Chem; 2019 Jul; 62(13):6398-6404. PubMed ID: 31251606
[TBL] [Abstract][Full Text] [Related]
38. A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities.
Lin D; Li F; Wu Q; Xie X; Wu W; Wu J; Chen Q; Liu S; He J
Sci Rep; 2016 Mar; 6():22790. PubMed ID: 26952867
[TBL] [Abstract][Full Text] [Related]
39. Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
Sokolov DN; Zarubaev VV; Shtro AA; Polovinka MP; Luzina OA; Komarova NI; Salakhutdinov NF; Kiselev OI
Bioorg Med Chem Lett; 2012 Dec; 22(23):7060-4. PubMed ID: 23099095
[TBL] [Abstract][Full Text] [Related]
40. In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives.
Zu M; Yang F; Zhou W; Liu A; Du G; Zheng L
Antiviral Res; 2012 Jun; 94(3):217-24. PubMed ID: 22521753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
